Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Aché Laboratórios Farmacêuticos S A currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, TCHERKASSKAYA, OLGA V, who is also identified as the busiest examiner with 1 busiest examiner pending case. The concentration of the portfolio is further evidenced by its presence in only 1 distinct art unit. This singular focus suggests that the company's current patent strategy is highly localized within a specific technical niche of the Biotechnology & Pharmaceuticals field.
The alignment of the 1 pending office action with the 1 distinct examiner creates a streamlined but concentrated prosecution environment. Because TCHERKASSKAYA, OLGA V is responsible for the 1 busiest examiner pending case, the outcome of this specific interaction will determine the immediate progress of the company's patent interests. Practitioners should note that with the 1 distinct art unit involved, there is no diversification of examiner perspectives across different USPTO divisions. This lack of variety means that the prosecution success for Aché Laboratórios Farmacêuticos S A is entirely dependent on the requirements and tendencies of the assigned personnel.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681117 | COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, COSMETIC USES OF A COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, ANTIOXIDANT DERMOCOSMETIC PRODUCT AND FOR PREVENTING SKIN AGING AND SKIN CARE METHOD | TCHERKASSKAYA, OLGA V | 36d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681117 | COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, COSMETIC USES OF A COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, ANTIOXIDANT DERMOCOSMETIC PRODUCT AND FOR PREVENTING SKIN AGING AND SKIN CARE METHOD | TCHERKASSKAYA, OLGA V | 36d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681117 | COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, COSMETIC USES OF A COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, ANTIOXIDANT DERMOCOSMETIC PRODUCT AND FOR PREVENTING SKIN AGING AND SKIN CARE METHOD | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | 36d overdue | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial